BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.


4/25/2008 6:50:53 AM

HARBIN, China, April 24 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (OTC Bulletin Board: CSKI - News), a pharmaceutical company for external use over-the-counter drugs in the People's Republic of China ("PRC"), today announced it acquired Heilongjiang Haina Pharmaceutical Inc. ("Haina Pharmaceutical"), a recently formed corporation organized under the laws of the PRC on April 18, 2008.

China Sky One Medical, Inc., through its indirect wholly owned subsidiary Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), consummated a transaction pursuant to an Equity Transfer Agreement with Heilongjiang Haina Pharmaceutical Inc., licensed as a wholesaler of traditional Chinese medicine, bio-medicines, bio-products, medicinal devices, antibiotics and chemical medicines.

Pursuant to the Equity Transfer Agreement, Harbin acquired 100% of the issued and outstanding capital stock of Haina Pharmaceutical from its three stockholders in consideration for payment of 3,000,000 RMB (approximately $428,571). TDR has been overseeing the operations of Haina Pharmaceutical since January 2008 as part of its due diligence prior to closing of this acquisition.

Haina Pharmaceutical does not have an established sales network and was acquired for its primary asset, a Good Supply Practice (GSP) license issued as of December 21, 2006 by the Heilongjiang office of the SFDA, and will expire on January 29, 2012. The SFDA recently started issuing such licenses to resellers of medicines in order to maintain certain quality controls. The GSP license enables China Sky One Medical to expand its sales of medicinal products without having to go through a lengthy license application process.

"We are pleased to complete the acquisition of Haina Pharmaceutical. By obtaining the GSP license, we now have the ability to further develop our sales channels in a timely manner," said Mr. Yan-qing Liu, Chairman, CEO and Director of China Sky One Medical, Inc.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

China Sky One Medical, Inc. Ms. Xiaoyan Han, CFO Tel: +86-1335-999-3681 Email: tdrhan@163.com

CCG Elite Investor Relations Inc. Mr. Crocker Coulson, President Tel: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com

Source: China Sky One Medical, Inc.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES